55346-97-9

Usage

Uses

Used in Organic Chemistry Research:
3,4-Difluoro-6-Nitrophenol is used as a key intermediate in the synthesis of various organic compounds. Its unique structural features, including the presence of fluorine and nitro groups, allow for specific reactivity patterns that are often exploited in the development of new chemical entities.
Used in Chemical Synthesis:
3,4-Difluoro-6-Nitrophenol is employed as a building block in the preparation of complex molecules and pharmaceuticals. Its reactivity and structural properties make it a valuable component in the synthesis of a wide range of chemical products, including agrochemicals, dyes, and specialty chemicals.
Used in Material Science:
3,4-Difluoro-6-Nitrophenol is utilized in the development of new materials with unique properties. Its incorporation into polymers and other materials can lead to enhanced performance characteristics, such as improved thermal stability, chemical resistance, or specific optical properties.
Used in Analytical Chemistry:
3,4-Difluoro-6-Nitrophenol serves as a reference compound or a standard in various analytical techniques, such as spectroscopy, chromatography, and electrochemistry. Its distinct chemical properties make it a useful tool for the calibration of analytical instruments and the validation of experimental methods.

InChI:InChI=1/C6H3F2NO3/c7-3-1-5(9(11)12)6(10)2-4(3)8/h1-2,10H

Upstream product

• 2713-33-9 3,4-difluorophenol 

Downstream Products

• 929885-18-7 tert-butyl 4-(2-fluoro-5-hydroxy-4-nitrophenyl)piperazine-1-carboxylate 
• 952339-92-3 2-(benzyloxy)-4,5-difluoroaniline 
• 1555700-11-2 7-(benzyloxy)-4,5-difluoro-3,3-dimethyl-1-(2-nitrophenyl)indoline 
• 1555700-08-7 7-(benzyloxy)-4,5-difluoro-3,3-dimethylindoline 
• 1555700-06-5 (2-(benzyloxy)-4,5-difluorophenyl)hydrazine 

Relevant academic research and scientific papers

1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to 1,3,4-oxadiazole derivative compounds having a histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, a use thereof in preparation of a medicament, a pharmaceutical composition comprising the same, a therapeutic method using the composition, and a method for preparing the same, and the 1,3,4-oxadiazole derivative compounds are represented by a following chemical formula (I).

Discovery of chromane propionic acid analogues as selective agonists of GPR120 with in Vivo activity in rodents

GPR120 (FFAR4) is a fatty acid sensing G protein coupled receptor (GPCR) that has been identified as a target for possible treatment of type 2 diabetes. A selective activator of GPR120 containing a chromane scaffold has been designed, synthesized, and eva

SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS

The present invention relates to a compound represented by formula (I) and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related di

5-AMINO-4-CARBAMOYL-PYRAZOLE COMPOUNDS AS SELECTIVE AND IRREVERSIBLE T790M OVER WT-EGFR KINASE INHIBITORS AND USE THEREOF????

Disclosed are compounds of Formula (I), pharmaceutical compositions comprising the same, processes for the preparation thereof, and the use thereof.

7-HYDROXY-INDOLINYL ANTAGONISTS OF P2Y1 RECEPTOR

The present invention provides compounds of Formula (I): Formula (I) as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of P2Y1 receptor which may be used medicaments.

CHEMICAL COMPOUNDS

The present invention relates to compounds of Formula (I) and/or Formula (Ia): and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds inhibit ALK kinase activity, and thus may be used for the tr

2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists

Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is R1-isoxazolyl, R1-oxadiazolyl, R1-dihydrofuranyl, R1-pyrazolyl, R1-imidazolyl, R1-pyrazinyl or R1-pyrimidinyl; R1 is 1, 2 or 3 substituents selected from H, alkyl, alkoxy and halo; Z is optionally substituted-aryl, or optionally substituted-heteroaryl; are disclosed, as well as their use in the treatment of central nervous system diseases, in particular Parkinson's disease and Extra Pyramidal Syndrome, pharmaceutical compositions comprising them, and combinations with other agents.

Novel compounds

The invention provides compounds of general formula (I) wherein Q, R, R2, R4, R5, R6, R7 and R8 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.